# Clinical Study of CD38\CS1 Chimeric Antigen Receptor T Cells in the Treatment of Refractory/Recurrent Multiple Myeloma

> **NCT06574958** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **The Second Hospital of Shandong University** · enrollment: 10 (estimated)

## Conditions studied

- ORR,OS,PFS

## Interventions

- **BIOLOGICAL:** CD38/CS1 injection

## Key facts

- **NCT ID:** NCT06574958
- **Lead sponsor:** The Second Hospital of Shandong University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-04-30
- **Primary completion:** 2025-01-15
- **Final completion:** 2025-01-15
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2024-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06574958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06574958, "Clinical Study of CD38\CS1 Chimeric Antigen Receptor T Cells in the Treatment of Refractory/Recurrent Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06574958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*